Zacks Investment Research Downgrades Supernus Pharmaceuticals (SUPN) to Strong Sell

Share on StockTwits

Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by Zacks Investment Research from a “hold” rating to a “strong sell” rating in a research note issued on Thursday.

According to Zacks, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. “

A number of other analysts have also weighed in on SUPN. BidaskClub upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 22nd. Piper Jaffray Companies set a $47.00 price objective on shares of Supernus Pharmaceuticals and gave the company a “hold” rating in a research note on Monday, July 2nd. ValuEngine upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, September 19th. Finally, Jefferies Financial Group raised their price objective on shares of Supernus Pharmaceuticals from $55.00 to $58.00 and gave the company a “buy” rating in a research note on Thursday, August 9th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $54.67.

Shares of Supernus Pharmaceuticals stock opened at $47.43 on Thursday. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.74 and a quick ratio of 2.54. The stock has a market capitalization of $2.63 billion, a P/E ratio of 37.64 and a beta of 0.79. Supernus Pharmaceuticals has a 1 year low of $33.30 and a 1 year high of $61.25.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported $0.57 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.43 by $0.14. The company had revenue of $99.54 million during the quarter, compared to analyst estimates of $101.01 million. Supernus Pharmaceuticals had a net margin of 24.17% and a return on equity of 30.57%. Equities research analysts expect that Supernus Pharmaceuticals will post 1.97 earnings per share for the current fiscal year.

Hedge funds have recently made changes to their positions in the company. SevenBridge Financial Group LLC bought a new stake in shares of Supernus Pharmaceuticals in the second quarter worth approximately $113,000. Cubist Systematic Strategies LLC bought a new stake in shares of Supernus Pharmaceuticals in the second quarter worth approximately $203,000. Everence Capital Management Inc. bought a new stake in shares of Supernus Pharmaceuticals in the second quarter worth approximately $205,000. Cim LLC bought a new stake in shares of Supernus Pharmaceuticals in the second quarter worth approximately $207,000. Finally, NumerixS Investment Technologies Inc bought a new stake in shares of Supernus Pharmaceuticals in the second quarter worth approximately $204,000. Hedge funds and other institutional investors own 97.45% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Featured Article: How to Use the New Google Finance Tool

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply